We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-106.00 | -0.87% | 12,050.00 | 12,036.00 | 12,038.00 | 12,178.00 | 12,010.00 | 12,092.00 | 1,635,146 | 16:35:23 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.34 | 186.61B |
TIDMAZN
RNS Number : 0977S
AstraZeneca PLC
16 December 2016
16 December 2016 13:00
Transaction by a Person Discharging Managerial Responsibilities
Disclosure under Articles 19(3) and 19(6) of the EU Market Abuse Regulation
On 16 December 2016, Pascal Soriot, a Director of the Company, notified us that, on 16 December 2016, he ceased to be beneficially interested in 59,951 AstraZeneca PLC Ordinary Shares of $0.25 each as a result of a gift of those shares to family members for nil consideration.
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 Details of the person discharging managerial responsibilities / person closely associated --- --------------------------------------------------------------- a) Name Pascal Soriot --- ------------------------- ------------------------------------ 2 Reason for the notification --- --------------------------------------------------------------- a) Position/status Chief Executive Officer --- ------------------------- ------------------------------------ b) Initial notification Initial notification /Amendment --- ------------------------- ------------------------------------ 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --- --------------------------------------------------------------- a) Name AstraZeneca PLC --- ------------------------- ------------------------------------ b) LEI Not applicable --- ------------------------- ------------------------------------ 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --- --------------------------------------------------------------- a) Description of Ordinary Shares of US$0.25 the financial each in AstraZeneca PLC instrument, type of instrument GB0009895292 Identification code --- ------------------------- ------------------------------------ b) Nature of the Gift of shares to family transaction members for nil consideration --- ------------------------- ------------------------------------ c) Price(s) and volume(s) Price(s) Volume(s) --------- ---------- 0 59,951 --------- ---------- --- ------------------------- ------------------------------------ d) Aggregated information Not applicable - single transaction - Aggregated volume - Price --- ------------------------- ------------------------------------ e) Date of the transaction 16 December 2016 --- ------------------------- ------------------------------------ f) Place of the transaction London --- ------------------------- ------------------------------------
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
Media Enquiries Neil Burrows UK/Global +44 203 749 5637 Vanessa Rhodes UK/Global +44 203 749 5736 Karen Birmingham UK/Global +44 203 749 5634 Rob Skelding UK/Global +44 203 749 5821 Jacob Lund Sweden +46 8 553 260 20 Michele Meixell US +1 302 885 2677 Investor Relations Thomas Kudsk Larsen +44 203 749 5712 Craig Marks Finance, Fixed Income, M&A +44 7881 615 764 Henry Wheeler Oncology +44 203 749 5797 Mitchell Chan Oncology +1 240 477 3771 Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970 Nick Stone Respiratory +44 203 749 5716 Christer Gruvris Autoimmunity, neuroscience & infection +44 203 749 5711 US toll free +1 866 381 7277
Adrian Kemp
Company Secretary, AstraZeneca PLC
-ENDS-
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUNVARNBAUAAA
(END) Dow Jones Newswires
December 16, 2016 08:00 ET (13:00 GMT)
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions